Plaintiff, a poultry breeding company, purchased a veterinary drug called Tiamulin 12.5% (Poultry) from Defendant in December 2010 to prevent microplasmosis in its poultry flocks. The drug was administered to various poultry sections (grandparent and parent stock) from 2-4 December 2010 according to Defendant's instructions (1g per litre for prevention). Shortly after administration, Plaintiff experienced high mortality rates, reduced egg production, and decreased cock fertility in the treated flocks. Birds displayed symptoms including leg paralysis, sitting on hocks, splayed feet, weakness, and inability to walk to feed and water. Post-mortem examinations by Plaintiff's veterinarian Dr. Hwingwiri revealed necrotic spots on livers, mucoid enteritis, and mild hemorrhage—all symptoms of chemical toxicity. Defendant had manufactured the Tiamulin itself but had failed to register it with the Medicines Control Authority of Zimbabwe (MCAZ) as required by law. Plaintiff had previously used Tiamulin from a South African supplier in August 2010 without problems, but experienced mild symptoms with Defendant's first batch in October 2010. Plaintiff claimed damages of US$178,294.00.